Jeffrey Michael Krase

Interests

No activities entered.

Courses

Scholarly Contributions

Journals/Publications

• Mehta, P., Herold, M., & Krase, J. (2022). Focal pigmentation of an eroded erythematous inguinal plaque in an older man. JAAD case reports, 27, 20-22.
• Krase, J. M., Dupont, J. P., Krase, J. M., Kasoff, W. S., & Dupont, J. P. (2021). Mohs Micrographic Surgery of the Scalp in a Patient With a Deep Brain Stimulator.. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 47(3), 412-414. doi:10.1097/dss.0000000000002308
• Krase, J. M., Shi, V. Y., Ludwig, C. M., & Krase, J. M. (2021). T Helper 2 Inhibitors in Allergic Contact Dermatitis.. Dermatitis, 32(1), 15-18. doi:10.1097/der.0000000000000616
  More info

  Clinical trials are currently underway to evaluate the benefit of dupilumab in treating allergic contact dermatitis (ACD). Dupilumab use has been reported to improve ACD reactions in some patients, but not all. Varying clinical responses to T helper 2 (TH2) inhibition challenge the classical view that ACD proceeds through a TH1-dominant pathway. Selective TH2 inhibitors, such as dupilumab, may attenuate ACD when the delayed hypersensitivity response is due to TH2-predominate activation; conversely, it may have no effect on ACD if it is elicited via TH1 or TH17 pathways. We hypothesize that allergen-specific T-cell responses and patient-specific factors both play an important role in determining which pathways are recalled in delayed hypersensitivity reactions.
• Krase, J. M., Shi, V. Y., Price, K. N., Ludwig, C. M., Lio, P. A., & Krase, J. M. (2021). A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis.. The Journal of dermatological treatment, 32(5), 503-506. doi:10.1080/09546634.2019.1682498
  More info

  Dear Editor,Atopic dermatitis (AD) is a chronic relapsing inflammatory dermatosis characterized by intense pruritus and rash. Its etiology is complex and influenced by an interplay of genetics, env...
• Davuluri, R., Krase, J. M., Cui, H., Goyal, U. D., Cheung, M. K., Hsu, C. C., & Yi, S. K. (2016). Image guided volumetric response during chemoradiotherapy for head and neck squamous cell carcinoma as a predictor of disease outcomes. American journal of otolaryngology, 37(4), 304-10.
  More info

  The goal of this study was to correlate volumetric image guided disease response to clinical outcomes in patients receiving chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC).
• Fernandez, J. M., Madsen, S., Krase, J. M., & Shi, V. Y. (2020). Classification and mitigation of negative injection experiences with biologic medications. Dermatologic therapy, 33(2), e13240.
  More info

  Injection site reactions with biologic medications are encountered with variable frequency. Although there is no clear definition, they commonly manifest with pain and irritation at the injection site. Previously proposed reaction classification systems may be impractical or insufficient, and more intuitive nomenclature may benefit clinical dermatologists and patients. Negative injection experiences (NIE) are common reasons for biologic medication nonadherence. Here we provide clinical classifications and recommendations for mitigating these reactions. We categorized NIEs into the following: (a) physical, due to the needle and injection process, (b) irritant, related to properties of the injected solution, and (c) allergic, both immediate and delayed.
• Hauptman, M., & Krase, J. M. (2020). Drug costs of Medicaid-covered therapies for pemphigus vulgaris treatment. Dermatology online journal, 26(12).
  More info

  Pemphigus vulgaris is the most common form of pemphigus affecting an estimated 30,000-40,000 people in the United States. Costs of systemic and immunoglobulin therapies for pemphigus vulgaris have remained persistently high. Herein, we address the current costs and changes in costs of immunosuppressive treatments, anti-inflammatory treatments, and immunoglobulin treatments covered by Medicaid for pemphigus vulgaris from 2013-2020.
• Ludwig, C. M., Krase, J. M., & Shi, V. Y. (2020). T Helper 2 Inhibitors in Allergic Contact Dermatitis. Dermatitis : contact, atopic, occupational, drug.
  More info

  Clinical trials are currently underway to evaluate the benefit of dupilumab in treating allergic contact dermatitis (ACD). Dupilumab use has been reported to improve ACD reactions in some patients, but not all. Varying clinical responses to T helper 2 (TH2) inhibition challenge the classical view that ACD proceeds through a TH1-dominant pathway. Selective TH2 inhibitors, such as dupilumab, may attenuate ACD when the delayed hypersensitivity response is due to TH2-predominate activation; conversely, it may have no effect on ACD if it is elicited via TH1 or TH17 pathways. We hypothesize that allergen-specific T-cell responses and patient-specific factors both play an important role in determining which pathways are recalled in delayed hypersensitivity reactions.
• Price, K. N., Hendricks, A. J., Goodrich, M. E., Krase, J. M., & Shi, V. Y. (2020). Widespread pustular eruption following probiotic use. Dermatology online journal, 26(11).
  More info

  A 26-year-old woman with Crohn disease and palmoplantar psoriasis on ustekinumab presented with a diffuse and intensely pruritic rash with a few pin-point pustules within days after initiation of an over-the-counter Align brand probiotic. Biopsy revealed psoriasiform and spongiotic dermatitis with spongiform subcorneal pustules and scattered eosinophils, consistent with acute generalized exanthematous pustulosis. Our case highlights a unique presentation of acute generalized exanthematous pustulosis following probiotic exposure with fewer than usual pustular lesions. IL23 suppression by ustekinumab may have contributed to the patient's reduced pustular presentation.
• Price, K. N., Krase, J. M., Loh, T. Y., Hsiao, J. L., & Shi, V. Y. (2020). Racial and ethnic disparities in global atopic dermatitis clinical trials. The British journal of dermatology, 183(2), 378-380.
• Shi, V. Y., Krase, J. M., Fernandez, J. M., & Madsen, S. (2020). Classification and mitigation of negative injection experiences with biologic medications. Dermatologic Therapy, 33(2). doi:10.1111/dth.13240
• Krase, J. M., Kasoff, W. S., & DuPont, J. P. (2019). Mohs Micrographic Surgery of the Scalp in a Patient With a Deep Brain Stimulator. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
• Ludwig, C. M., Krase, J. M., Price, K. N., Lio, P. A., & Shi, V. Y. (2019). A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis. The Journal of dermatological treatment, 1-4.
• Mata, E., Loh, T. Y., Ludwig, C., Price, K. N., Fernandez, J. M., Krase, J. M., & Shi, V. Y. (2019). Pharmacy costs of systemic and topical medications for atopic dermatitis. The Journal of dermatological treatment, 1-3.
• Maarouf, M., Wickenheiser, M., Krase, J. M., Wolter, S., & Shi, V. Y. (2018). Trimethoprim-sulfamethoxazole-induced drug reaction with eosinophilia and systemic symptoms in a child with congenital renal disease. Pediatric dermatology, 35(6), e391-e392.
  More info

  We present a special case of an 8-year-old girl diagnosed with severe drug reaction with eosinophilia and systemic symptoms due to trimethoprim-sulfamethoxazole for urinary tract infection prophylaxis for congenital vesicoureteral reflux. The patient is believed to have developed drug reaction with eosinophilia and systemic symptoms because of her underlying renal disease.
• Krase, J. M., Gottesman, S. P., & Goldberg, G. N. (2017). Recurrence of Argyria Post Q-Switched Laser Treatment. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 43(10), 1308-1311.